Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:ENGNNASDAQ:IMNMNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.85$1.83$1.60▼$3.14$713.00M1.061.34 million shs1.46 million shsENGNenGene$3.67-0.5%$4.55$3.50▼$15.00$187.09M-0.36126,621 shs26,688 shsIMNMImmunome$7.43-2.6%$7.81$5.15▼$16.81$646.50M2912,738 shs1.70 million shsXERSXeris Biopharma$4.47+4.0%$4.61$1.72▼$6.07$699.51M1.11.92 million shs2.34 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group-2.63%0.00%+8.19%-9.76%-30.19%ENGNenGene+0.14%-7.88%-18.11%-46.59%-76.21%IMNMImmunome-10.24%-10.66%+28.67%-35.50%-50.65%XERSXeris Biopharma-7.33%-2.49%-2.49%+17.17%+126.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.4109 of 5 stars2.04.00.00.02.40.01.3ENGNenGene3.5749 of 5 stars4.53.00.00.02.92.50.6IMNMImmunome2.6274 of 5 stars4.50.00.00.03.32.50.0XERSXeris Biopharma3.5552 of 5 stars3.41.00.04.22.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/A$3.5089.19% UpsideENGNenGene 3.00Buy$23.29534.49% UpsideIMNMImmunome 3.00Buy$25.33240.96% UpsideXERSXeris Biopharma 2.80Moderate Buy$6.1036.37% UpsideCurrent Analyst Ratings BreakdownLatest ENGN, IMNM, CRON, and XERS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/11/2025IMNMImmunomeLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.003/10/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.003/7/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.003/7/2025XERSXeris BiopharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.50(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.62M6.06N/AN/A$2.87 per share0.64ENGNenGeneN/AN/AN/AN/A$6.17 per shareN/AIMNMImmunome$9.04M71.51N/AN/A$2.77 per share2.68XERSXeris Biopharma$203.07M3.44N/AN/A($0.05) per share-89.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.10N/A61.671.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)IMNMImmunome-$106.81M-$5.17N/AN/AN/A-3,014.59%-48.63%-41.62%5/13/2025 (Estimated)XERSXeris Biopharma-$62.26M-$0.38N/AN/AN/A-33.69%N/A-17.38%5/8/2025 (Estimated)Latest ENGN, IMNM, CRON, and XERS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMNMImmunome-$0.67N/AN/AN/A$0.46 millionN/A5/8/2025Q1 2025XERSXeris Biopharma-$0.07N/AN/AN/A$57.61 millionN/A3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AENGNenGene$1.5843.08%N/AN/A N/AIMNMImmunomeN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05ENGNenGene0.0816.8716.87IMNMImmunomeN/A6.176.17XERSXeris BiopharmaN/A1.791.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%ENGNenGene64.16%IMNMImmunome44.58%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%ENGNenGene13.70%IMNMImmunome8.60%XERSXeris Biopharma4.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.41 million356.14 millionOptionableENGNenGene3150.98 million38.16 millionN/AIMNMImmunome4087.01 million72.92 millionOptionableXERSXeris Biopharma290156.39 million142.28 millionOptionableENGN, IMNM, CRON, and XERS HeadlinesRecent News About These Companies4XERS : Earnings Outlook For Xeris Biopharma HoldingsMay 7 at 2:53 PM | benzinga.comXeris Biopharma Holdings: Looking For More Growth In Q1 EarningsMay 7 at 12:13 PM | seekingalpha.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton CorpMay 7 at 6:28 AM | marketbeat.comXeris Biopharma (XERS) Expected to Announce Earnings on ThursdayMay 7 at 2:35 AM | americanbankingnews.comXeris Biopharma (XERS) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comXeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase - Time to Buy?April 30, 2025 | marketbeat.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To ProfitApril 26, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23, 2025 | msn.comJPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 22, 2025 | marketbeat.comRenaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 21, 2025 | marketbeat.comEAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What HappenedApril 18, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short InterestApril 18, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?April 17, 2025 | marketbeat.comKennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 16, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.April 16, 2025 | marketbeat.comCenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 12, 2025 | marketbeat.comXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comStrength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?March 20, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesENGN, IMNM, CRON, and XERS Company DescriptionsCronos Group NASDAQ:CRON$1.85 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.enGene NASDAQ:ENGN$3.67 -0.02 (-0.54%) Closing price 04:00 PM EasternExtended Trading$3.66 -0.01 (-0.27%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Immunome NASDAQ:IMNM$7.43 -0.20 (-2.62%) Closing price 04:00 PM EasternExtended Trading$7.34 -0.09 (-1.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Xeris Biopharma NASDAQ:XERS$4.47 +0.17 (+4.02%) Closing price 03:59 PM EasternExtended Trading$4.47 0.00 (-0.07%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
